METTL3 and hematologic disorder: METTL3, the core methyltransferase involved in m6A modification, has been reported to play significant roles in normal hematopoiesis and hematological malignancies including AML, acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), and lymphoma [14, 15].